All In Biotech

Drug Trial Radar · NCT07333183

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Dec 2026

Study completion Jan 2028

Sponsor

Lead sponsor
Pulmovant, Inc.Industry
Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

Conditions

  • Pulmonary Hypertension
  • Interstitial Lung Disease (ILD)
  • Lung Diseases
  • Vascular Diseases
  • Cardiovascular Diseases
  • Fibrosis

Interventions

  • inhaled mosliciguatDrug

    Dose level 1, 2, or 3 for inhalation

  • Dry Powder InhalerDevice

    Dry powder inhaler for mosliciguat delivery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuationTime frame: Baseline, Week 16

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Santa Barbara, California · Recruiting

  • Clinical Research Site

    Torrance, California · Recruiting

  • Clinical Research Site

    Kissimmee, Florida · Recruiting

  • Clinical Research Site

    Chicago, Illinois · Recruiting

  • Clinical Research Site

    Kansas City, Kansas · Recruiting

  • Clinical Research Site

    Boston, Massachusetts · Recruiting

  • Clinical Research Site

    Ann Arbor, Michigan · Recruiting

  • Clinical Research Site

    Detroit, Michigan · Recruiting

  • Clinical Research Site

    Albuquerque, New Mexico · Recruiting

  • Clinical Research Site

    Greensboro, North Carolina · Recruiting

  • Clinical Research Site

    Providence, Rhode Island · Recruiting

  • Clinical Research Site

    Charleston, South Carolina · Recruiting

  • Clinical Research Site

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.